Product Name: PAK1 (141-147) pS144
Product Number: PE-04AOI95
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: PAK1 (141-147) pS144

Product Use: Services as a blocking peptide for use with the PAK1-pS144 rabbit polyclonal antibody (Cat. No.: AB-PK748) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located just after the PBD. The major site of phosphorylation of PAK1. S144 phosphorylation stimulates phosphotransferase activity and regulates cytoskeletal reorganization, and intracellular location.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: KYM-pS-FTD

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1144.2 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: PAK1 - pS144 phosphosite-specific antibody (Cat. No.: AB-PK748)

Scientific Background: PAK1 is a protein-serine/threonine kinase that is a member of the STE group of protein kinases in the STE20 family, and PAKA subfamily. This kinase is highly expressed and widely distributed in most tested human tissues. PAK1 has been implicated in the regulation of cytoskeletal organization, and cell proliferation and survival, morphology, motility and transformation. Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region at the N-terminus of PAK1 releases monomers from the autoinhibited dimer, enables phosphorylation at T423 and activation of its phosphotransferase activity. It is also activated by binding to GTP-bound Cdc42, independent of the phosphorylation state of T423. Phosphorylation of S144, S149, and T423 increases PAK1's phosphotransferase activity, whereas phosphorylation of T84 (by OXSR1) and Y212 inhibits its phosphotransferase activity. Phosphorylation of S21 inhibits binding of Nck and PIX. PAK1 may be a therapeutic target in B-Raf wild-type melanoma. Knockdown of PAK1 has been shown to inhibit the proliferation of mutant KRAS colon cancer cells.